weather icon Mostly Cloudy

Study offers rare advance for some pancreatic cancer patients

CHICAGO — Patients with pancreatic cancer that hadn’t spread lived substantially longer on a four-drug combo than on a single standard cancer drug,

It’s a rare advance for a tough-to-beat cancer, and experts say it could be practice-changing for a small group of patients whose pancreatic cancer is diagnosed early enough to be removed by surgery.

Results were reported Monday at a medical meeting in Chicago.

The study tested folfirinox against the standard treatment, Gemzar. Folfirinox combines four chemotherapy drugs.

Two-thirds of patients given folfirinox were alive after three years versus half of those given Gemzar.

Nearly 500 patients in France and Canada were enrolled.

Don't miss the big stories. Like us on Facebook.
Rural Nevadans at greater risk of suicide

Data from the state show that residents of rural Nevada take their lives at a rate 43 percent higher than in Clark County and 56 percent higher than in Washoe County.